|Articles|May 15, 2002
Growth is forecast: Alcon IPO raises $2.5 billion in partial Nestle divestiture
Fort Worth, TX-Alcon Inc.'s successful initial public offering (IPO) not only confirms the stability of the company, but positions it well for future growth and investment, according to company officials and analysts.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5











































.png)


